First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.
Fiche publication
Date publication
août 2012
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Pr NERICH Virginie, Pr PIVOT Xavier
Tous les auteurs :
Nerich V, Bazan F, Compagnat F, Dobi E, Villanueva C, Chaigneau L, Perrin S, Voidey A, Pivot X, Limat S
Lien Pubmed
Résumé
To carry out a cost minimisation analysis including a comparison of the costs arising from first-line treatment by bevacizumab plus docetaxel (BD) versus bevacizumab plus paclitaxel (BP) of patients with metastatic breast cancer (mBC).
Mots clés
Aged, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, economics, Bevacizumab, Breast Neoplasms, drug therapy, Bridged-Ring Compounds, administration & dosage, Disease-Free Survival, Female, Humans, Middle Aged, Neoplasm Metastasis, Taxoids, administration & dosage
Référence
Anticancer Res.. 2012 Aug;32(8):3547-52